Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2)

Date

08 Oct 2016

Session

Poster Display

Presenters

Andrew Zhu

Citation

Annals of Oncology (2016) 27 (6): 207-242. 10.1093/annonc/mdw371

Authors

A.X. Zhu1, P.R. Galle2, M. Kudo3, R. Finn4, L. Yang5, P. Abada6, J.M. Llovet7

Author affiliations

  • 1 Medicine, Dana-Farber Cancer Institute, 02215 - Boston/US
  • 2 Internal Medicine/gastroenterology, Johannes Gutenberg-University Mainz, 55131 - Mainz/DE
  • 3 Hepatology, Gastroenterology, Kinki University, Osaka/JP
  • 4 Medicine, UCLA, Santa Monica/US
  • 5 Biostatistics, Eli Lilly and Company, 08807 - Bridgewater/US
  • 6 Oncology, Eli Lilly and Company, 46285 - Indianapolis/US
  • 7 Department Of Medicine, Icahn School of Medicine at Mount Sinai, 10029 - New York/US
More

Resources

Abstract 1780

Background

Ramucirumab (RAM) is a humanized IgG1 monoclonal antibody that inhibits VEGF-A, C and D activation of the vascular endothelial growth factor receptor 2 (VEGFR2). The Phase 3 REACH study assessed RAM versus placebo (PBO) in the treatment of patients with advanced hepatocellular carcinoma (HCC) after prior sorafenib. Significant improvement in overall survival (OS) in the overall population (N = 565) was not achieved (Hazard Ratio [HR] = 0.866; 95% CI 0.717–1.046; p = 0.1391); median OS was 9.2m for RAM and 7.6m for PBO. However, a meaningful improvement in OS was observed in a pre-specified subgroup of patients with baseline alpha-fetoprotein (AFP) ≥400ng/mL (N = 250)(HR = 0.674; p = 0.0059); median OS was 7.8m for RAM and 4.2m for PBO. The safety profile of RAM in HCC patients was considered manageable.

Trial design

REACH-2 is a randomized, double-blind, placebo-controlled phase III study of RAM and best supportive care (BSC) vs placebo and BSC in patients with HCC and elevated baseline AFP following prior therapy with sorafenib. Eligible patients will be randomized 2:1 to receive RAM (8mg/kg, IV) or PBO on Day 1 of each 14-day cycle until disease progression or other discontinuation criteria. Eligible patients must have a diagnosis of HCC (tissue or tumor with classical imaging characteristics); prior sorafenib; Child-Pugh score 5 or 6; Barcelona Clinic Liver Cancer Stage C or Stage B disease not amenable/refractory to locoregional therapy; AFP ≥400 ng/mL; ECOG performance status of 0 or 1. Patients with history of encephalopathy, ongoing clinically meaningful ascites, liver transplant, or hepatic locoregional therapy after sorafenib are not eligible. The primary objective is to assess OS for patients treated with RAM vs PBO. Target enrollment is 399 patients with final analysis at 318 events (20% censoring). Secondary objectives include progression free survival, objective response rate, safety, and patient focused outcomes. Additional objectives include assessment of biomarkers relevant to angiogenesis and HCC.

Clinical trial identification

NCT02435433

Legal entity responsible for the study

Eli Lilly and Company

Funding

Eli Lilly and Company

Disclosure

A.X. Zhu: Research funding from Eli Lilly and Company.

P.R. Galle: Honoraria, Advisory Role, and Travel from Bayer, BMS, Lilly, Transgene, Arqule; Speaker for Bayer.

M. Kudo: Honoraria from Bayer, Eisai, Ajinomoto, Kaken Pharma; Advisory Role for Taiho, Bayer, BMS, Kowa, Chugai. Research funding from Taiho, Bayer, BMS, Kowa, Chugai, Lilly, Novartis, Pfizer.

R. Finn: Consultant: Pfizer, Merck, Bayer, Novartis, Bristol Meyers Squibb.

L. Yang: Eli Lilly and Company employee and stock owner.

P. Abada: Eli Lilly and Company employee and stock owner.

J.M. Llovet: Honoraria, Consulting/Advisory roles for Eli Lilly, BMS, Merck, Blueprint, Eisai, Biocompatibles, Guerbert, Roche, Bayer, Genentech, Boehringer-Ingelheim, GSK, Celsion, Novartis. Research funding from Eli Lilly, Bayer, Novartis, Boehringer-Ingelheim.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings